Treatment Information


Prostate Cancer treatment details. Biologic therapy.

Weill Medical College of Cornell University, New York, N.Y., United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, N.Y.
Treatments:Biologic therapyHospital:Weill Medical College of Cornell University
Date:Jul 2005


Patients: This Phase I study involved 35 men with hormone-refractory protstate cancer. The median age was 69 years.

Treatment: The treatment consisted of one biological agent: J591, an isotope-labeled monoclonal antibody that recognizes the prostate specific antigen that is expressed in tumor cells.

Toxicity: Grade 3-4 toxicities included neutropenia, thrombocytopenia, and elevated liver enzymes.

Results: The median overall survival was not reported. The authors were encouraged with the antibody's relatively low toxicity and ability to target tumor tissue.

Correspondence: Neil H. Bander, M.D.